Avalo Therapeutics, Inc.
AVTX Healthcare Biotechnology
Avalo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $59,000.00, down 86.6% from fiscal 2024. In the quarter to June 2026, revenue fell 70.1%, EPS grew 56.8% and free cash flow grew 75.7%, each against the same quarter a year earlier.
Follow AVTX
Avalo Therapeutics, Inc. (AVTX) Altman Z-score
Avalo Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is −2.13, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −2.13 | 0.64 |
| FY2024 | −2.77 | 23.46 |
| FY2023 | −26.23 | (10.76) |
| FY2022 | −15.47 | (10.01) |
| FY2021 | −5.46 | (0.26) |
| FY2020 | −5.20 | (8.91) |
| FY2019 | 3.71 | 5.92 |
| FY2018 | −2.21 | (4.39) |
| FY2017 | 2.17 | 27.04 |
| FY2016 | −24.87 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.79 | — | 0.95 | |
| Retained earnings / total assets | (3.85) | — | −5.39 | |
| EBIT / total assets | (0.63) | — | −2.07 | |
| Market value of equity / total liabilities | 7.29 | — | 4.37 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −2.13 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −8.95 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| GYRE Gyre Therapeutics, Inc. compare | 16.8× |
| WVE WAVE Life Sciences Ltd. compare | 11.3× |
| AVTX Avalo Therapeutics, Inc. | −2.1× |
| SLDB Solid Biosciences Inc. compare | −2.9× |
| PRME Prime Medicine, Inc. compare | −3.7× |
| CLYM Climb Bio, Inc. compare | — |
| AURA Aura Biosciences, Inc. compare | — |
| DSGN Design Therapeutics, Inc. compare | — |
| NVCT Nuvectis Pharma, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets